16 Jul, 2021 RNAi Roundtable: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis
Posted at 10:51h
in Capella
On July 16, 2021, we hosted an online RNAi Roundtable to review the progress with patisiran and vutrisiran, in development for the treatment of transthyretin-mediated amyloidosis.
Access the replay
View the presentation
Rena Denoncourt
Vice President, ATTR Amyloidosis Franchise Lead
Dawn
Caregiver and hATTR Amyloidosis Patient
Rebecca Shilling, M.D.
Director, Clinical Research
Patrick Jay, M.D.
Director, Clinical Research
Mat Maurer, M.D.
Columbia University Medical Center, Arnold and Arlene Goldstein Professor of Cardiology
John Vest, M.D.
Vice President, Clinical Research
